A multi-marker blood test combining microRNA, protein, and hormone measurements can accurately detect endometriosis and identify cases missed by standard imaging, offering a potential new diagnostic pathway for symptomatic women.
Endometriosis, in which tissue similar to the uterine lining grows outside the uterus, affects an estimated 5 to 10 percent of women of reproductive age and up to half of those with infertility. It is associated with pelvic pain, menstrual irregularities, and reduced quality of life, yet diagnosis is often delayed by several years because symptoms overlap with other conditions. The current gold standard remains laparoscopic surgery with histological confirmation, an invasive procedure with variable accuracy that depends on lesion visibility and operator expertise.
The new assay integrates seven circulating biomarkers—three microRNAs measured by qPCR, three proteins, and one steroid hormone—alongside patient age and body mass index, using a machine learning model to classify disease status. In a validation cohort, the test demonstrated high diagnostic accuracy and maintained consistent performance across different phases of the menstrual cycle, addressing a longstanding challenge in endometriosis testing.
The study, published in Journal of Minimally Invasive Gynecology, highlights the growing importance of multi-omic diagnostics that combine molecular and clinical variables into a single interpretive score. Unlike traditional single-analyte tests such as CA125, the panel captures multiple biological processes, including immune signaling, hormonal variation, and tissue remodeling, which together reflect the systemic nature of the disease.
The blood test identified a substantial proportion of histologically confirmed cases that were not detected by ultrasound or MRI, suggesting it could reduce false negatives in routine clinical pathways. This is particularly relevant given that imaging performance can vary depending on operator expertise and lesion characteristics.
The test also addresses a major clinical gap: delayed diagnosis. Endometriosis often takes years to confirm, in part because current gold-standard diagnosis relies on invasive laparoscopy. A blood-based approach could enable earlier triage of symptomatic patients, guiding decisions on referral, imaging, or empirical treatment.
From a workflow perspective, the assay uses established laboratory platforms, including real-time PCR and automated immunoassay systems, making it compatible with existing clinical laboratory infrastructure. The addition of machine learning for result interpretation reflects a broader shift toward algorithm-driven diagnostics, where complex biomarker patterns are translated into clinically actionable outputs.
The findings also reinforce the concept of endometriosis as a systemic condition, with detectable circulating molecular signatures rather than a purely localized pelvic disease. This supports the use of peripheral blood as a diagnostic medium.
Although further validation in larger and more diverse populations is needed, the study demonstrates how integrated biomarker panels could enhance diagnostic accuracy, reduce reliance on invasive procedures, and enable earlier intervention in endometriosis care.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
